Boston Scientific Corporation (0HOY.L) LSE

95.88

-0.2176(-0.23%)

Updated at December 24 05:33PM

Currency In USD

Boston Scientific Corporation

Address

300 Boston Scientific Way

Marlborough, MA 01752-1234

United States of America

Phone

508 683 4000

Sector

Healthcare

Industry

Medical - Equipment & Services

Employees

53000

First IPO Date

January 29, 2018

Key Executives

NameTitlePayYear Born
Michael F. MahoneyChairman, President & Chief Executive Officer5.34M1965
Jeffrey MirvissExecutive Vice President & President of Peripheral Interventions1.5M1966
Arthur Crosswell ButcherExecutive Vice President and Group President of MedSurg & Asia Pacific1.71M1971
Joseph FitzgeraldExecutive VP & Group President of Cardiology2.2M1964
Adam SmithGeneral Manager of Global Sales & Marketing0N/A
Jonathan R MonsonExecutive VP & CFO0N/A
Miriam O'sullivanSenior VP & Chief Human Resources Officer0N/A
John Bradley SorensonExecutive Vice President of Global Operations01968
Vance R. BrownSenior VP, General Counsel & Corporate Secretary01970
Brenda BeckerSenior Vice President of Global Government Affairs01960
Emily WoodworthSenior Vice President, Global Controller & Chief Accounting Officer01978

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.